Skip to main content

Valdecoxib Pregnancy and Breastfeeding Warnings

Valdecoxib is also known as: Bextra

Valdecoxib Pregnancy Warnings

Valdecoxib has been assigned to a pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. Data from human pregnancy studies are not available. Valdecoxib should only be given during pregnancy when benefit outweighs risk.

The manufacturer recommends that valdecoxib be avoided in late pregnancy (third trimester) due to the risk of premature closure of the ductus arteriosus.

See references

Valdecoxib Breastfeeding Warnings

There are no data on the excretion of valdecoxib into human milk. Valdecoxib and its active metabolite are excreted in the milk of lactating rats. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue valdecoxib, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Bextra (valdecoxib)." Pharmacia and Upjohn (2001):

References for breastfeeding information

  1. "Product Information. Bextra (valdecoxib)." Pharmacia and Upjohn (2001):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.